TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Protara Therapeutics, Inc. (TARA) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D (1.4) | D+ (1.8) | D (1.3) | C+ (2.6) | C- (1.9) |
| 2026-11-08 | A- (3.9) | D (1.4) | D+ (1.8) | D (1.2) | C+ (2.6) | C (2.2) |
| 2026-11-01 | C+ (2.5) | D (1.4) | C- (1.9) | D (1.3) | C+ (2.7) | C- (2.0) |
| 2026-10-25 | B+ (3.7) | D (1.4) | C- (1.9) | D (1.3) | C+ (2.6) | C (2.2) |
| 2026-10-18 | B+ (3.7) | D (1.4) | C- (1.9) | D (1.4) | C+ (2.6) | C (2.2) |